What to Expect From Celldex Therapeutics, Inc. in 2018 [The Motley Fool]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: The Motley Fool
After a decades-long journey, 2018 could be the year Celldex Therapeutics transitions from a clinical-stage biotech to one with a product to sell. Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) entered 2018 with its lead drug in a fully enrolled pivotal trial. The situation echoes the clinical-stage biotech's position at the beginning of 2016; later, an unexpected failure left investors scarred . This year should be much different. The one we've all been waiting for Finding 327 advanced-stage, triple-negative breast cancer patients with tumors that express high levels of a specific surface protein that glembatumumab vedotin (glemba) targets wasn't easy, but Celldex finally got it done. Investigators randomized the last patients into groups receiving the company's lead candidate or standard chemotherapy last August, but won't let anyone know which group they're in until 203 patients show signs of disease progression. Image source: Getty Images. In early 2016,
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria [Yahoo! Finance]Yahoo! Finance
- Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaGlobeNewswire
- Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.MarketBeat
- Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceGlobeNewswire
CLDX
Earnings
- 2/26/24 - Miss
CLDX
Sec Filings
- 3/1/24 - Form 8-K
- 3/1/24 - Form 424B5
- 2/28/24 - Form 424B5
- CLDX's page on the SEC website